Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]CBP8 PET and DCE-MRI to Assess Immunosuppression in Non-IPF ILD
NCT07572383Phase 2Recruiting
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Gallium Ga 68 NODAGA-CBP8 in interstitial lung disease (ILD), pulmonary fibrosis (PF). Started May 2026; status: recruiting.
02
Drugs
Gallium Ga 68 NODAGA-CBP8
03
Conditions
interstitial lung disease (ILD)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT07572383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572383.